Academy of Diabetes, Thyroid, and Endocrine - Site 840-129 — El Paso, Texas

Academy of Diabetes, Thyroid, and Endocrine - Site 840-129 is a clinical research site located in El Paso, Texas, United States 79935.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Academy of Diabetes, Thyroid, and Endocrine - Site 840-129 has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Thyroid Eye Disease.

Sponsors: Tourmaline Bio, Inc., a Novartis Company.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in El Paso

Browse all research sites in Texas · View every site in El Paso

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Academy of Diabetes, Thyroid, and Endocrine - Site 840-129?

Academy of Diabetes, Thyroid, and Endocrine - Site 840-129 has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Academy of Diabetes, Thyroid, and Endocrine - Site 840-129 conducted?

Academy of Diabetes, Thyroid, and Endocrine - Site 840-129 has 1 clinical trials on record, with 1 currently active. Their work covers Thyroid Eye Disease.

Is Academy of Diabetes, Thyroid, and Endocrine - Site 840-129 accredited by Crixeo Clinical Trials?

Academy of Diabetes, Thyroid, and Endocrine - Site 840-129 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Academy of Diabetes, Thyroid, and Endocrine - Site 840-129?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.